Skip to main content
NVCR
NASDAQ Industrial Applications And Services

NovoCure Q2 Revenue Jumps 16%, Adjusted EBITDA Turns Positive; Guidance Raised

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$16.76
Mkt Cap
$1.803B
52W Low
$9.82
52W High
$18.92
52W Position info
71% above low
Off High info
11% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

NVCR sits 71% above its 52-week low of $9.82.

Summary

NovoCure reported Q2 2026 revenue of $183.6M (+16% YoY) and positive Adjusted EBITDA of $10.8M. Full-year guidance was raised on both top and bottom lines. The Optune Pax launch contributed 285 active patients.


Key Events · Earnings and Guidance · NVCR

  • Record Revenue and Patient Growth

    Q2 net revenues reached $183.6M, up 16% year-over-year, driven by 18% growth in global active patients to 5,128. Optune Gio remains the core driver with 4,636 active patients.

  • Adjusted EBITDA Turns Positive

    Adjusted EBITDA swung to $10.8M from a loss of $9.9M a year ago, reflecting operating leverage and lower R&D costs. Net loss narrowed to $15.7M from $40.1M.

  • Optune Pax Launch Gains Momentum

    Optune Pax contributed $1.6M in revenue and reached 285 active patients in the U.S. following its CE Mark approval in June. The launch is a key growth catalyst.

  • Full-Year Guidance Raised

    Management lifted 2026 revenue guidance to $710M-$725M (from $690M-$710M) and Adjusted EBITDA to $0M-$15M (from a loss of $15M to breakeven), signaling confidence in the commercial trajectory.


Analysis · NVCR · Industrial Applications And Services

NovoCure delivered its strongest quarter yet, with record revenue and a swing to positive Adjusted EBITDA. The Optune Pax launch is gaining traction, adding 285 active patients. Management raised full-year revenue and EBITDA guidance, signaling confidence in the commercial ramp. The balance sheet remains solid with $440.6M in cash, providing ample runway. This quarter marks a turning point toward profitability after the TRIDENT trial setback.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NVCR was trading at $16.76 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.82 to $18.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NVCR - Latest Insights

NVCR
Nov 09, 2026, 6:59 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.95
Real-time Price: $10.94 info
Change: -$3.01 (-22%) info
Market Cap: $1.279B info
NVCR
Oct 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.25
Real-time Price: $10.94 info
Change: -$3.31 (-23%) info
Market Cap: $1.279B info
NVCR
Oct 29, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.34
Real-time Price: $10.94 info
Change: -$4.40 (-29%) info
Market Cap: $1.279B info
NVCR
Oct 29, 2026, 6:59 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.25
Real-time Price: $10.94 info
Change: -$3.31 (-23%) info
Market Cap: $1.279B info
NVCR
Oct 01, 2026, 9:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $16.06
Real-time Price: $10.94 info
Change: -$5.12 (-32%) info
Market Cap: $1.279B info